Almost half of persons who inject drugs (PWID) with endocarditis will die within five years; women are disproportionately affected
LONDON, Ont. and REGINA, Sask. - People who inject drugs are dying at an alarming rate from endocarditis, a serious but treatable heart-valve infection.
But their odds of survival improve dramatically, even five years after their first admission to hospital, if they’re treated not just for heart infection but are also provided with addiction support while in hospital, a Canadian study shows.
The study also highlights that women who inject drugs are particularly vulnerable to endocarditis and are affected in disproportionately high numbers.
“Endocarditis is potentially lethal and always costly,” says Dr. Michael Silverman, an infectious diseases researcher at St. Joseph’s Health Care London and a scientist at Lawson Health Research Institute in London, Ont. “It takes a huge toll on the health-care system and, more importantly, it claims too many lives that could otherwise be saved.”
Silverman has co-authored a landmark new paper, with University of Saskatchewan researchers Dr. Stuart Skinner, Dr. Cara Spence and Janica Adams, in JAMA Network Open.
“Our study, the first of its kind, shows that we can dramatically improve the short- and long-term survival among persons who inject drugs by treating more than just the infection. We need to provide in-hospital counselling and addiction care,” Silverman says. Without that support, he says, these patients experience opiate-withdrawal symptoms which often results in patient-initiated discharge from hospital before their treatment for endocarditis is complete.
Endocarditis is a severe infection of the lining of the heart muscle. Its treatment includes intravenous antibiotics and often in-hospital care for about a month. In about 20 per cent of cases, discharged patients had subsequent endocarditis infections and multiple hospital stays.
Researchers examined hospital and post-hospital records of 764 people with endocarditis from 2007 to 2023 in London, Ont., at St. Joseph’s and at London Health Sciences Centre, and in Regina – two centres where city-wide hospital records made identifying long term survival possible. Funded by St. Joseph’s Health Care Foundation, this study is the first to look at survival over five years after admission to hospital.
Fifty-six per cent of patients were persons who injected drugs (PWIDs). Their five-year mortality rate was 49 per cent. Most deaths from endocarditis itself were within the first year, with deaths after that more commonly related to the complications of addiction.
“Our study shows the effectiveness of prioritizing more comprehensive addiction treatment upon hospital admission and linking to care afterwards. While these are part of the standard of care in both Regina and London, they are not available in many North American hospitals,” says Spence.
Skinner, an assistant professor of infectious diseases at USask, adds, “At these mortality rates, endocarditis amongst PWIDs should be regarded as a health emergency, with a need to use all available life-saving resources.”
Silverman notes that women made up slightly more than 50 per cent of PWIDs with endocarditis, despite making up only one-third of PWIDs overall in both Canada and the USA. The reasons for this disproportionate number of women who inject drugs with endocarditis are unclear but may be related to their having others perform the injecting and because they are often disempowered, being among the last to inject, with previously used equipment, he says.
Women in urban centers had higher long-term mortality than those in rural areas, likely related to the urban complications of homelessness, the sex trade and violence. Skinner notes young rural women often have better survival rates because many are connected to communities of support. “It speaks to the importance of community in the context of treating addiction,” he says.
Five per cent of the women were pregnant on admission to hospital, and there was high fetal and maternal mortality. Researchers highlighted the importance of offering these women access to contraceptive options. Contraception is rarely offered when patients are admitted with serious unrelated conditions, but then an opportunity to provide care to these marginalized women is often missed.
Says Skinner, “All people should have access to fundamental things like health care and housing, and there’s a standard empathy we need to have for everyone. These are moms and dads and kids. The average age of this group is 31 for women patients and 38 for men. That's a large population of vulnerable people who are very ill or dying at far too young an age.”
To arrange interviews with Dr. Michael Silverman please contact:
Deb (Flaherty) Van Brenk, Communication Consultant
St. Joseph’s Health Care London
Cell: 226 577-1429 or 519 318-0657
@email
To arrange interviews with Dr. Stuart Skinner or Dr. Cara Spence, please contact:
Victoria Dinh
USask Media Relations
306 966-5487
@email
Lawson Health Research Institute is one of Canada’s top hospital-based research institutes, tackling the most pressing challenges in health care. As the research institute of London Health Sciences Centre and St. Joseph’s Health Care London, our innovation happens where care is delivered. Lawson research teams are at the leading-edge of science with the goal of improving health and the delivery of care for patients. Working in partnership with Western University, our researchers are encouraged to pursue their curiosity, collaborate often and share their discoveries widely. Research conducted through Lawson makes a difference in the lives of patients, families and communities around the world. To learn more, visit www.lawsonresearch.ca.